Navigation Links
Lotus Pharmaceuticals, Inc. to Exhibit at the 62nd PHARMCHINA

BEIJING, Nov. 24 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company") a growing developer and producer of prescriptions drugs and licensed national seller of pharmaceutical products in the People's Republic China, today reported it will exhibit at the 62nd PHARMCHINA as a member of the Beijing pharmaceutical delegation.

Time: November 26-28, 2009

Venue: International Convention Center, Chengdu

The Beijing delegation features more than twenty pharmaceutical companies from Beijing, including Beijing Shuanghe Group, Beijing Pharmaceutical Group, and Tongrentang. As a member of the delegates, Lotus will continue to market its drugs that have established certain market share in China and introduce three potential new drugs that are subject to the State Food and Drug Administration's approval. These drugs include Laveo-Bambutero for asthma, Gliclazide-Controlled Release Tablets for type 2 diabetes and Isosorbide Mononitrate-Sustained Release Tablets for coronary artery disease.


PHARMCHINA is the largest and most recognized exhibition in the Chinese pharmaceutical industry over the last thirty years. With a gross floor area of more than 60,000 square meters and leading professional and academic forums, it attracts more than 1,900 exhibitors. PHARMCHINA is a diversified trading and exchange platform for pharmaceutical companies. For more information, please see .

About Lotus Pharmaceuticals, Inc. ( )

Lotus Pharmaceuticals, Inc. is a growing developer and producer of prescription drugs and a licensed national seller of pharmaceutical items in the People's Republic of China. Lotus operates Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' current drug development pipeline is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. More than 8,000 products are sold by Liang Fang directly and indirectly through its national sales channels to hospitals, clinics and drugs stores in 30 provinces.

    For more information, please contact:

    Lotus Pharmaceuticals, Inc.
     Yan ZENG, CFO
     Tel:   +86-10-6389-9868

SOURCE Lotus Pharmaceuticals, Inc.

Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Lotus Pharmaceuticals, Inc. Reports Third-Quarter 2009 Results
2. Lotus Pharmaceuticals, Inc.s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials
3. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
4. Bioniche Pharma and Academic Pharmaceuticals, Inc. Announce the Introduction of Sotalol Hydrochloride Injection
5. Brookstone Pharmaceuticals, LLC becomes Acella Pharmaceuticals, LLC
6. Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for the First Quarter of Fiscal Year 2010
7. Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results
8. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
10. Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results
11. BioMarin Acquires Huxley Pharmaceuticals, Inc.
Post Your Comments:
(Date:11/30/2015)... Diplomat Pharmacy, Inc. (NYSE: DPLO ) ... Free Press as a Top Workplace , among the ... work for in 2015. ... annually, based on employee surveys rating company leadership, career opportunities, ... based solely on employee feedback. The survey is conducted by ...
(Date:11/30/2015)...  IBA Molecular North America, Inc. (IBAMNA), a U.S. ... that as of January 1, 2016, it will do ... to rebrand the company reflects a refined vision for ... close relationship with Zevacor Molecular.  Both IBAMNA and Zevacor ... Peter Burke , Vice President Sales ...
(Date:11/30/2015)... 30, 2015 Baxalta Incorporated (NYSE: ... dedicated to delivering transformative therapies to patients ... today announced the launch and first shipments ... extended circulating half-life recombinant factor VIII (rFVIII) ... ADVATE [Antihemophilic Factor (Recombinant)]. The treatment was ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... An ... directory is specialized and only includes chiropractic clinics in the US. , The ... trustworthy alternative health practitioner when back pain sets in. When people are experiencing ...
(Date:11/30/2015)... ... November 30, 2015 , ... In ... Halloween festivities, the Word of Life Christian Church of Flint, MI, hosted a ... a giant 1.25 ton pile of candy dubbed “Candy Mountain”. , A Forever ...
(Date:11/30/2015)... ... November 30, 2015 , ... During ... fundraising campaign to raise funds for its research, education, support, and advocacy efforts. ... organization’s annual funding. , The Mesothelioma Applied Research Foundation, which also goes by ...
(Date:11/30/2015)... ... November 30, 2015 , ... The ... in Dallas, TX, on January 29 and 30, 2016. The course welcomes dental ... of their practices, to learn how to better succeed in the modern dental ...
(Date:11/30/2015)... ... November 30, 2015 , ... HemoTreat™ has announced that the ... ointment to its website. , “Our goal is simple:” says Michael Blasco, HemoTreat’s ... the comparison chart and ingredient list allows our customers to quickly see why, ...
Breaking Medicine News(10 mins):